corporate_fare

Allrock Bio Inc.

Address: 12 Washington Street

Sponsor Overview

assignment

Specializations

Pulmonary Arterial Hypertension

Allrock Bio Inc. is involved in clinical research centered on pulmonary arterial hypertension, with attention to treatments that address elevated pulmonary vascular resistance and related hemodynamic burden.

Right heart and pulmonary circulation disorders
Vascular resistance in PAH
Oral therapy for pulmonary hypertension

The sponsor’s research interest extends to the clinical management of chronic pulmonary vascular disease in adults requiring ongoing treatment.

Pulmonary Hypertension Associated with Interstitial Lung Disease

The company also studies pulmonary hypertension linked to interstitial lung disease, reflecting a focus on complex lung disease settings where vascular and respiratory pathology overlap.

ILD-associated pulmonary hypertension
Chronic respiratory disease
Vascular complications of interstitial lung disease

This area includes patients with mixed pulmonary and fibrotic lung involvement, where symptom burden and disease progression are closely linked.

Safety and Tolerability

Allrock Bio Inc. places clinical emphasis on safety and tolerability in oral administration for cardiopulmonary conditions, with interest in treatment suitability for long-term use.

Adverse event monitoring
Oral medication tolerability
Chronic treatment acceptability

Its research profile includes evaluation of how investigational therapy is handled alongside standard of care in patients with serious pulmonary vascular disease.

Trial Name	Country	Status
A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)	France Germany Italy Latvia Poland Spain	Recruiting